Development of metastatic HER2+ breast cancer is independent of the adaptive immune system

被引:21
作者
Ciampricotti, Metamia
Vrijland, Kim
Hau, Cheei-Sing
Pemovska, Tea
Doornebal, Chris W.
Speksnijder, Ewoud N.
Wartha, Katharina [2 ]
Jonkers, Jos
de Visser, Karin E. [1 ]
机构
[1] Netherlands Canc Inst, Dept Mol Biol, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands
[2] Roche Diagnost GmbH, Pharma Res & Early Dev, Penzberg, Germany
关键词
breast cancer; metastasis; Her2/neu; adaptive immune system; innate immune system; immunosurveillance; HER-2/NEU TRANSGENIC MICE; PANCREATIC-ISLET TUMORS; T-CELL; MAMMARY CARCINOMAS; OVARIAN-CANCER; BALB/C MICE; IMMUNOSURVEILLANCE; CARCINOGENESIS; ANGIOGENESIS; RESPONSES;
D O I
10.1002/path.2837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumour-modulating effects of the endogenous adaptive immune system are rather paradoxical. Whereas some clinical and experimental observations offer compelling evidence for the existence of immunosurveillance, other studies have revealed promoting effects of the adaptive immune system on primary cancer development and metastatic disease. We examined the functional significance of the adaptive immune system as a regulator of spontaneous HER2(+) breast tumourigenesis and pulmonary metastasis formation, using the MMTV-NeuT mouse model in which mammary carcinogenesis is induced by transgenic expression of the activated HER2/neu oncogene. Although T and B lymphocytes infiltrate human and experimental HER2(+) breast tumours, genetic elimination of the adaptive immune system does not affect development of premalignant hyperplasias or primary breast cancers. In addition, we demonstrate that pulmonary metastasis formation in MMTV-NeuT mice is not dependent on the adaptive immune system. Thus, our findings reveal that spontaneous HER2-driven mammary tumourigenesis and metastasis formation are neither suppressed, nor altered by immunosurveillance mechanisms, nor promoted by the adaptive immune system. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:56 / 66
页数:11
相关论文
共 51 条
[1]   High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates [J].
Alexe, Gabricla ;
Dalgin, Gul S. ;
Scanfeld, Daniel ;
Tamayo, Pablo ;
Mesirov, Jill P. ;
DeLisi, Charles ;
Harris, Lyndsay ;
Barnard, Nicola ;
Martel, Maritza ;
Levine, Arnold J. ;
Ganesan, Shridar ;
Bhanot, Gyan .
CANCER RESEARCH, 2007, 67 (22) :10669-10676
[2]   Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance [J].
Ambrosino, Elena ;
Spadaro, Michela ;
Iezzi, Manuela ;
Curcio, Claudia ;
Forni, Guido ;
Musiani, Piero ;
Wei, Wei-Zen ;
Cavallo, Federica .
CANCER RESEARCH, 2006, 66 (15) :7734-7740
[3]   FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis [J].
Andreu, Pauline ;
Johansson, Magnus ;
Affara, Nesrine I. ;
Pucci, Ferdinando ;
Tan, Tingting ;
Junankar, Simon ;
Korets, Lidiya ;
Lam, Julia ;
Tawfik, David ;
DeNardo, David G. ;
Naldini, Luigi ;
de Visser, Karin E. ;
De Palma, Michele ;
Coussens, Lisa M. .
CANCER CELL, 2010, 17 (02) :121-134
[4]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[5]   Tumour necrosis factor and cancer [J].
Balkwill, Frances .
NATURE REVIEWS CANCER, 2009, 9 (05) :361-371
[6]   Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice [J].
Boggio, K ;
Nicoletti, G ;
Di Carlo, E ;
Cavallo, F ;
Landuzzi, L ;
Melani, C ;
Giovarelli, M ;
Rossi, I ;
Nanni, P ;
De Giovanni, C ;
Bouchard, P ;
Wolf, S ;
Modesti, A ;
Musiani, P ;
Lollini, PL ;
Colombo, MP ;
Forni, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (03) :589-596
[7]   The distinctive nature of HER2-positive breast cancers [J].
Burstein, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1652-1654
[8]   Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].
Casanovas, O ;
Hicklin, DJ ;
Bergers, G ;
Hanahan, D .
CANCER CELL, 2005, 8 (04) :299-309
[9]   Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death [J].
Casares, N ;
Pequignot, MO ;
Tesniere, A ;
Ghiringhelli, F ;
Roux, S ;
Chaput, N ;
Schmitt, E ;
Hamai, A ;
Hervas-Stubbs, S ;
Obeid, M ;
Coutant, F ;
Métivier, D ;
Pichard, E ;
Aucouturier, P ;
Pierron, G ;
Garrido, C ;
Zitvogel, L ;
Kroemer, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) :1691-1701
[10]   Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? [J].
de Visser, Karin E. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (10) :1531-1539